Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Estrogen receptor beta as a novel drug target for mutiple cancer indications : Preclinical development of KB9520
| Reference number | 2014-00467 |
| Coordinator | Karo Bio Aktiebolag |
| Funding from Vinnova | SEK 4 756 616 |
| Project duration | April 2014 - March 2015 |
| Status | Completed |
